Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cyclin-dependent kinases (CDKs) are a family of Ser/Thr kinases involved in cell cycle and transcriptional regulation. CDK9 regulates transcriptional elongation and this unique property has made it a potential target for several diseases. Due to the conserved ATP binding site, designing selective CDK9 inhibitors has been challenging. Here we report our continued efforts in the optimization of 2,4,5-tri-substituted pyrimidine compounds as potent and selective CDK9 inhibitors. The most selective compound 30m was >100-fold selective for CDK9 over CDK1 and CDK2. These compounds showed broad anti-proliferative activities in various solid tumour cell lines and patient-derived chronic lymphocytic leukaemia (CLL) cells. Decreased phosphorylation of the carboxyl terminal domain (CTD) of RNAPII at Ser-2 and down-regulation of anti-apoptotic protein Mcl-1 were confirmed in both the ovarian cancer model A2780 and patient-derived CLL cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmech.2021.113244 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Translocation renal cell carcinoma (tRCC) is an aggressive kidney cancer driven by gene fusions of the transcription factor. is essential in tRCC but dispensable in normal cells, presenting an attractive but pharmacologically challenging therapeutic target. We show that the basic helix-loop-helix (bHLH) domain of TFE3 is crucial for chromatin binding and transcriptional function.
View Article and Find Full Text PDFTotal Synthesis of Rohitukine and Dysoline and Their Anticancer Analogues Flavopiridol and IIIM-290.
ACS Omega
August 2025
Department of Natural Products & Medicinal Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana 500007, India.
Rohitukine is a naturally occurring piperidine alkaloid that has led to the discovery of several potent CDK9/T1 inhibitors, including flavopiridol and IIIM-290. (-)-(3,4)-1-Methyl-4-(2,4,6-trimethoxyphenyl)-piperidin-3-ol serves as a crucial chiral intermediate in the synthesis of rohitukine and its analogues. In this paper, we describe the asymmetric synthesis of the chiral alcohol through the diastereoselective reduction of (+)-()-1-methyl-4-(2,4,6-trimethoxyphenyl)-piperidin-3-one in >90% yield and ≥99.
View Article and Find Full Text PDFBackground: Colorectal cancer (CRC) is the second deadliest cancer worldwide and new treatment options are urgently needed. Cyclin dependent kinase 9 (CDK9) promotes aberrant RNA transcription in cancer and is a promising target for cancer therapies.
Methods: Using CRC cell lines as well as newly established patient-derived organoid models of CRC, we studied the clinically promising CDK9 inhibitors (AZD4573, BAY1125152/VIP152/enitociclib, and NVP2) to determine their therapeutic potential.
Repurposing flavopiridol as an inhaled therapeutic for pulmonary fibrosis.
Eur J Pharmacol
August 2025
Department of Translational Orthopedic Research, Houston Methodist Research Institute, Houston, TX, 77030, USA; Orthopedics & Sports Medicine, Houston Methodist Hospital, Houston, TX, 77030, USA. Electronic address:
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease with limited therapeutic options. Cyclin-dependent kinase 9 (CDK9), a key transcriptional regulator, has been implicated in fibrotic diseases, but no therapies targeting CDK9 have been developed for IPF. This investigation found that CDK9 expression was significantly elevated in IPF lung fibroblasts, correlating with an enhanced fibrogenic transcriptional profile and phenotype.
View Article and Find Full Text PDFThe oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.
Blood Neoplasia
August 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
The antiapoptotic protein myeloid cell leukemia 1 (Mcl-1) promotes cell survival in acute myeloid leukemia (AML), and its overexpression is associated with resistance to venetoclax. Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, indirectly decreases Mcl-1 protein expression and has synergistic activity with venetoclax in AML preclinical models. We hypothesized that voruciclib in combination with venetoclax would induce responses in patients with AML with disease progression after venetoclax therapy.
View Article and Find Full Text PDF